337-OR: Tirzepatide Improved Markers of Islet-Cell Function (Fasting Glucagon and HOMA2-B) and Insulin Sensitivity (Fasting Insulin and HOMA2-IR) Compared with Semaglutide in People with Type 2 Diabetes
Year: 2022
Type: article
Source: Diabetes
DOI: 10.2337/db22-337-or
Authors: KATELYN BROWN, LAURA FERNANDEZ LANDO, BRANDON BERGMAN, MELISSA K. THOMAS, BING LIU, CLARE LEE
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4281992279